SCHEDULE: Paradigm Capital Management Boosts Integra Lifesciences Stake

Paradigm Capital Management, Inc. has amended its Schedule 13G filing to report beneficial ownership of 3,439,098 shares, representing 4.42% of Integra Lifesciences Holdings Corp.'s common stock as of March 31, 2026.

Summary

• Paradigm Capital Management, Inc. (Paradigm) has filed an amendment to its Schedule 13G, reporting its beneficial ownership of Integra Lifesciences Holdings Corp. (Integra) common stock.
• As of March 31, 2026, Paradigm beneficially owns 3,439,098 shares of Integra's common stock.
• This ownership stake represents 4.42% of the total class of securities.
• Paradigm holds sole voting power and sole dispositive power over these shares.
• The filing indicates that these securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of Integra.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a significant but not overwhelming stake by a known institutional investor. The lack of aggressive language or new strategic initiatives suggests a holding pattern rather than a strong conviction play.

Positives

• Institutional investor Paradigm Capital Management has a significant stake (4.42%) in Integra Lifesciences.
• Paradigm holds sole voting and dispositive power, suggesting a clear investment conviction.
• The filing confirms the shares are held in the ordinary course of business, implying a standard investment strategy.

Negatives

• The filing does not indicate any new strategic initiatives or significant changes in ownership strategy beyond reporting the current stake.
• The ownership percentage, while substantial, does not represent a controlling interest.

Risks

• No specific risks are detailed in this Schedule 13G filing, as it primarily reports ownership status.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future performance. It solely reports current ownership status.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in public companies. Paradigm Capital Management's filing indicates a notable position in Integra Lifesciences, a player in the medical technology sector, without suggesting any immediate activist intent.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional holding, which can be viewed positively as a sign of investor confidence, but it does not signal any immediate change in corporate control or strategy that would directly impact share price.
• Management: The filing reinforces that Paradigm is not currently seeking to influence control, allowing management to continue with its existing strategic plans.
• Creditors: No direct impact is indicated as the filing is purely about equity ownership.

Next Steps

• Paradigm Capital Management will continue to hold its position in Integra Lifesciences, subject to market conditions and its investment strategy.
• Integra Lifesciences will continue its operations as a medical technology company.

Key Dates

Keywords

Integra Lifesciences, Paradigm Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Investment Holding